Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 12 Best Performing Stocks in the Last 3 Months. On October 16, Oppenheimer raised its price target on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) from $115 to $250 and kept an Outperform rating. This decision came after positive topline results from Praxis Precision Medicines, Inc.’s (NASDAQ:PRAX) 3 Essential3 trial of ulixacaltamide for essential tremor (ET), a nervous system condition that causes involuntary shaking, mostly in the hands and ...